Journal of Vasculitis

Department of Nephrology, Renal Registrar, Addenbrooke’s Hospital, Cambridge, Cambridgeshire, CB2 0QQ, UK

Publications

• Review Article   
  Management of ANCA-associated Vasculitis
  Author(s): Hannah Stacey*
  
  Background: Antibody-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a potentially life-threatening condition. Multiorgan involvement can occur and is associated with significant morbidity, particularly if there is lung and renal disease. Aggressive and early immunosuppressant therapy is the cornerstone of management and has transformed ANCA-associated vasculitis (AAV) into a chronic relapsing condition. Remission induction therapy typically consists of high dose glucocorticoids in combination with cyclophosphamide or rituximab or both for several months. Plasma exchange is recommended for life-threatening disease, although evidence is conflicting. Remission maintenance therapy is often continued for up to two years and usually consists of glucocorticoids, azathioprine or rituximab. Methotrexate and mycophenolate mofetil (MMF) c.. Read More»
  DOI: 10.37421/2471-9544.2023.9.180

  Abstract HTML PDF